Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONO-2017-01 phase III study in Japanese patients with primary generalized tonic-clonic seizures
jRCT2031210624Phase 3Recruiting
- Sponsor
- Ono Pharmaceutical
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of cenobamate in primary generalized tonic-clonic seizure (PGTCS) and idiopathic epilepsy (IGE), sponsored by Ono Pharmaceutical. Primary endpoint: Percent change in PGTC seizure frequency per 28 days. Started Jul 2022; status: recruiting.
02
Drugs
cenobamate
03
Conditions
primary generalized tonic-clonic seizure (PGTCS)idiopathic epilepsy (IGE)
Beyond the preview
Go deeper on jRCT2031210624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210624.